Literature DB >> 22522436

The pituitary tumor transforming gene in thyroid cancer.

G D Lewy1, N Sharma, R I Seed, V E Smith, K Boelaert, C J McCabe.   

Abstract

The pituitary tumor transforming gene (PTTG) is a multifunctional proto-oncogene that is over-expressed in various tumors including thyroid carcinomas, where it is a prognostic indicator of tumor recurrence. PTTG has potent transforming capabilities in vitro and in vivo, and many studies have investigated the potential mechanisms by which PTTG contributes to tumorigenesis. As the human securin, PTTG is involved in critical mechanisms of cell cycle regulation, whereby aberrant expression induces aneuploidy. PTTG may further contribute to tumorigenesis through its role in DNA damage response pathways and via complex interactions with hormones and growth factors. Furthermore, PTTG over-expression negatively impacts upon the efficacy of radioiodine therapy in thyroid cancer, through repression of expression and function of the sodium iodide symporter. Given its various roles at all disease stages, PTTG appears to be an important oncogene in thyroid cancer. This review discusses the current knowledge of PTTG with particular focus on its role in thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522436     DOI: 10.3275/8332

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  132 in total

1.  Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function.

Authors:  L Pei
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

2.  Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; M Davis; P E Goretzki; P G Hoffman
Journal:  J Surg Res       Date:  1985-02       Impact factor: 2.192

Review 3.  Gene expression profile of human thyroid cancer in relation to its mutational status.

Authors:  Dagmara Rusinek; Sylwia Szpak-Ulczok; Barbara Jarzab
Journal:  J Mol Endocrinol       Date:  2011-11-02       Impact factor: 5.098

Review 4.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

Authors:  Michelle C Mendoza; E Emrah Er; John Blenis
Journal:  Trends Biochem Sci       Date:  2011-04-30       Impact factor: 13.807

5.  Prevalence of Ras mutations in thyroid neoplasia.

Authors:  C T Esapa; S J Johnson; P Kendall-Taylor; T W Lennard; P E Harris
Journal:  Clin Endocrinol (Oxf)       Date:  1999-04       Impact factor: 3.478

6.  Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells.

Authors:  Run Yu; Wenge Lu; Jiandong Chen; Chris J McCabe; Shlomo Melmed
Journal:  Endocrinology       Date:  2003-07-24       Impact factor: 4.736

Review 7.  The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.

Authors:  Bryan McIver; Stefan K G Grebe; Norman L Eberhardt
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2004-09

8.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

Authors:  Marina N Nikiforova; Edna T Kimura; Manoj Gandhi; Paul W Biddinger; Jeffrey A Knauf; Fulvio Basolo; Zhaowen Zhu; Riccardo Giannini; Giuliana Salvatore; Alfredo Fusco; Massimo Santoro; James A Fagin; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

10.  BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.

Authors:  T Takano; Y Ito; M Hirokawa; H Yoshida; A Miyauchi
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

View more
  5 in total

1.  Cancer: Novel target to enhance radioiodine uptake in thyroid cancer.

Authors:  Gregory A Brent; Takahiko Kogai
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

2.  The anaphase promoting complex regulates yeast lifespan and rDNA stability by targeting Fob1 for degradation.

Authors:  Johannes Menzel; Mackenzie E Malo; Cynthia Chan; Martin Prusinkiewicz; Terra G Arnason; Troy A A Harkness
Journal:  Genetics       Date:  2013-12-20       Impact factor: 4.562

3.  PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.

Authors:  Seema Parte; Irma Virant-Klun; Manish Patankar; Surinder K Batra; Alex Straughn; Sham S Kakar
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 6.692

4.  Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients.

Authors:  Raffaele Pezzani; Loris Bertazza; Elisabetta Cavedon; Simona Censi; Jacopo Manso; Sara Watutantrige-Fernando; Gianmaria Pennelli; Francesca Galuppini; Susi Barollo; Caterina Mian
Journal:  Int J Endocrinol       Date:  2019-02-18       Impact factor: 3.257

5.  Are pre-miR-146a and PTTG1 associated with papillary thyroid cancer?

Authors:  Marco Marino; Valentina Cirello; Valentina Gnarini; Carla Colombo; Elisa Pignatti; Livio Casarini; Chiara Diazzi; Vincenzo Rochira; Katia Cioni; Bruno Madeo; Cesare Carani; Manuela Simoni; Laura Fugazzola
Journal:  Endocr Connect       Date:  2013-10-22       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.